Login / Signup

Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.

Katsuaki AsakawaKazutaka YoshizawaAmi AokiYosuke KimuraTakahiro TanakaKazumasa OhashiMasachika HayashiToshiaki KikuchiShinji SatoToshinori Takada
Published in: Clinical rheumatology (2020)
Anti-MDA-5-positive ADM-ILD had poorer survival than anti-ARS-ILD. IP-10 seems to be most deeply involved in the pathophysiology of anti-MDA-5-associated ADM-ILD.Key Points• To clarify differences in the inflammatory and immunological features of anti-MDA-5-positive ADM-ILD and anti-ARS-ILD, we performed an observational study to measure serum cytokine concentrations before treatment using a multiplex immunoassay system.• Multivariate logistic regression models revealed that IP-10 was associated with the most significant relative risk for ADM-ILD with anti-MDA-5 antibodies.• Levels of IP-10 were elevated considerably in anti-MDA-5-positive survivors and nonsurvivors compared with the levels in anti-ARS patients.• These results suggest that IP-10 is the most deeply involved in the pathophysiology of anti-MDA-5-positive ADM-ILD.
Keyphrases
  • interstitial lung disease
  • breast cancer cells
  • systemic sclerosis
  • young adults
  • high throughput
  • single cell
  • cell death
  • sensitive detection
  • patient reported